Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132105 | 1.00 | KMT2A (0.50) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL13651179 | 1.00 | KMT2A (0.50) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL4131315 | 0.80 | PTPN1 (0.65) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL4131316 | 0.80 | PTPN1 (0.65) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL4125367 | 0.79 | MEN1 (0.69) | KMT2AHSP90AA1MAPK1MEN1PTPN1 | |
| SCHEMBL4125372 | 0.79 | MEN1 (0.69) | KMT2AHSP90AA1MAPK1MEN1PTPN1 | |
| SCHEMBL4125376 | 0.79 | MEN1 (0.69) | KMT2AHSP90AA1MAPK1MEN1PTPN1 | |
| SCHEMBL13657468 | 0.72 | CMA1 (0.64) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL2592761 | 0.71 | KMT2A (0.74) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL5768481 | 0.69 | CMA1 (0.76) | KMT2APKMTSHRSMN1; SMN2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | KOTNIK MIHA | 2009-10-01 | — | — | US | disclosed |
| EP-1916249-A1 | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents | LEK Pharmaceuticals D.D. (SI) | 2008-04-30 | — | — | EP | disclosed |
| EP-1916249-A1 | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents | LEK Pharmaceuticals D.D. (SI) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008043733-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | LEK PHARMACEUTICAL D.D. (SI) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | XDH, TXLNA, Q6ZSR9 | KMT2A 1459/4885PKM 2638/4885TSHR 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.